Histone deacetylases (HDACs): characterization of the classical HDAC family.

Transcriptional regulation in eukaryotes occurs within a chromatin setting, and is strongly influenced by the post-translational modification of histones, the building blocks of chromatin, such as methylation, phosphorylation and acetylation. Acetylation is probably the best understood of these modifications: hyperacetylation leads to an increase in the expression of particular genes, and hypoacetylation has the opposite effect. Many studies have identified several large, multisubunit enzyme complexes that are responsible for the targeted deacetylation of histones. The aim of this review is to give a comprehensive overview of the structure, function and tissue distribution of members of the classical histone deacetylase (HDAC) family, in order to gain insight into the regulation of gene expression through HDAC activity. SAGE (serial analysis of gene expression) data show that HDACs are generally expressed in almost all tissues investigated. Surprisingly, no major differences were observed between the expression pattern in normal and malignant tissues. However, significant variation in HDAC expression was observed within tissue types. HDAC inhibitors have been shown to induce specific changes in gene expression and to influence a variety of other processes, including growth arrest, differentiation, cytotoxicity and induction of apoptosis. This challenging field has generated many fascinating results which will ultimately lead to a better understanding of the mechanism of gene transcription as a whole.

[1]  N. Davidson,et al.  Role of DNA Methylation and Histone Acetylation in Steroid Receptor Expression in Breast Cancer , 2001, Journal of Mammary Gland Biology and Neoplasia.

[2]  A. Wozniak,et al.  Chronic Oral Administration of CI-994: A Phase I Study , 2004, Investigational New Drugs.

[3]  E. Olson,et al.  Association of Class II Histone Deacetylases with Heterochromatin Protein 1: Potential Role for Histone Methylation in Control of Muscle Differentiation , 2002, Molecular and Cellular Biology.

[4]  Fred Asselbergs,et al.  Cloning and Functional Characterization of HDAC11, a Novel Member of the Human Histone Deacetylase Family* , 2002, The Journal of Biological Chemistry.

[5]  Daniel Delorme,et al.  Structurally simple trichostatin A-like straight chain hydroxamates as potent histone deacetylase inhibitors. , 2002, Journal of medicinal chemistry.

[6]  K. Min,et al.  Regulation of lifespan by histone deacetylase , 2002, Ageing Research Reviews.

[7]  Peter A. Jones,et al.  The fundamental role of epigenetic events in cancer , 2002, Nature Reviews Genetics.

[8]  K. Resing,et al.  Phosphatase Inhibition Leads to Histone Deacetylases 1 and 2 Phosphorylation and Disruption of Corepressor Interactions* , 2002, The Journal of Biological Chemistry.

[9]  Xiao-Fan Wang,et al.  HDAC6 is a microtubule-associated deacetylase , 2002, Nature.

[10]  Ioannis Xenarios,et al.  Microarray Deacetylation Maps Determine Genome-Wide Functions for Yeast Histone Deacetylases , 2002, Cell.

[11]  John J. Andreucci,et al.  Composition and Function of AP-1 Transcription Complexes during Muscle Cell Differentiation* , 2002, The Journal of Biological Chemistry.

[12]  L. Neckers,et al.  Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. , 2002, Journal of the National Cancer Institute.

[13]  Y. Ozawa [Histone deacetylase-targeted anti-leukemia therapy]. , 2002, [Rinsho ketsueki] The Japanese journal of clinical hematology.

[14]  A. Caudy,et al.  Functional Divergence between Histone Deacetylases in Fission Yeast by Distinct Cellular Localization and In Vivo Specificity , 2002, Molecular and Cellular Biology.

[15]  Ricky W. Johnstone,et al.  Histone-deacetylase inhibitors: novel drugs for the treatment of cancer , 2002, Nature Reviews Drug Discovery.

[16]  Weidong Wang,et al.  Specific targeting and constitutive association of histone deacetylase complexes during transcriptional repression. , 2002, Genes & development.

[17]  T. Fojo,et al.  Histone deacetylase inhibitor FR901228 enhances adenovirus infection of hematopoietic cells. , 2002, Blood.

[18]  Wen‐Ming Yang,et al.  Functional Domains of Histone Deacetylase-3* , 2002, The Journal of Biological Chemistry.

[19]  A. Zetterberg,et al.  The histone deacetylase inhibitor trichostatin A derepresses the telomerase reverse transcriptase (hTERT) gene in human cells. , 2002, Experimental cell research.

[20]  V. Richon,et al.  Histone deacetylase inhibitors: a new class of potential therapeutic agents for cancer treatment. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  S. Bates,et al.  Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  N. Bertos,et al.  Identification of HDAC10, a novel class II human histone deacetylase containing a leucine-rich domain. , 2002, Nucleic acids research.

[23]  P. Atadja,et al.  Isolation and Characterization of a Novel Class II Histone Deacetylase, HDAC10* , 2002, The Journal of Biological Chemistry.

[24]  R. Warrell,et al.  Frequent mutations in the ligand-binding domain of PML-RARalpha after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in vivo. , 2002, Blood.

[25]  C. Tei,et al.  Histone deacetylase inhibitors suppress telomerase reverse transcriptase mRNA expression in prostate cancer cells. , 2002, International journal of cancer.

[26]  T. Yao,et al.  Molecular Cloning and Characterization of a Novel Histone Deacetylase HDAC10* , 2002, The Journal of Biological Chemistry.

[27]  K. Helin,et al.  The role of p53 and pRB in apoptosis and cancer. , 2002, Current opinion in genetics & development.

[28]  H. Kwon,et al.  Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis , 2002, International journal of cancer.

[29]  Manfred Jung,et al.  Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. , 2002, Journal of medicinal chemistry.

[30]  E. Nicolas,et al.  Functional and physical interaction between the histone methyl transferase Suv39H1 and histone deacetylases. , 2002, Nucleic acids research.

[31]  R. Evans,et al.  Isolation and Characterization of Mammalian HDAC10, a Novel Histone Deacetylase* , 2002, The Journal of Biological Chemistry.

[32]  F. Dequiedt,et al.  Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. , 2002, Molecular cell.

[33]  Ping Zhu,et al.  Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells , 2001, The EMBO journal.

[34]  S. Schreiber,et al.  Histone Deacetylase 1 Phosphorylation Promotes Enzymatic Activity and Complex Formation* , 2001, The Journal of Biological Chemistry.

[35]  A. Verdel,et al.  Mechanism for Nucleocytoplasmic Shuttling of Histone Deacetylase 7* , 2001, The Journal of Biological Chemistry.

[36]  R. Marmorstein Structure of histone deacetylases: insights into substrate recognition and catalysis. , 2001, Structure.

[37]  N. Rosen,et al.  The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. , 2001, Cancer research.

[38]  P. Marks,et al.  Histone deacetylases and cancer: causes and therapies , 2001, Nature Reviews Cancer.

[39]  G. Bae,et al.  Activation of p21WAF1/Cip1 Transcription through Sp1 Sites by Histone Deacetylase Inhibitor Apicidin , 2001, The Journal of Biological Chemistry.

[40]  Design and synthesis of a novel class of histone deacetylase inhibitors. , 2001, Bioorganic & medicinal chemistry letters.

[41]  D. Lavelle,et al.  Histone deacetylase inhibitors increase p21WAF1 and induce apoptosis of human myeloma cell lines independent of decreased IL‐6 receptor expression , 2001, American journal of hematology.

[42]  V. Richon,et al.  Histone deacetylase inhibitors as new cancer drugs , 2001, Current opinion in oncology.

[43]  P. Pandolfi,et al.  Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. , 2001, The Journal of clinical investigation.

[44]  W. Wilson,et al.  Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. , 2001, Blood.

[45]  Sandy D. Westerheide,et al.  The p65 (RelA) Subunit of NF-κB Interacts with the Histone Deacetylase (HDAC) Corepressors HDAC1 and HDAC2 To Negatively Regulate Gene Expression , 2001, Molecular and Cellular Biology.

[46]  J. Herman,et al.  Synergistic activation of functional estrogen receptor (ER)-α by DNA methyltransferase and histone deacetylase inhibition in human ER-α-negative breast cancer cells , 2001 .

[47]  T. Ekström,et al.  Differential expression of class I HDACs: roles of cell density and cell cycle. , 2001, International journal of oncology.

[48]  E. Olson,et al.  Control of muscle development by dueling HATs and HDACs. , 2001, Current opinion in genetics & development.

[49]  S. Pavey,et al.  Up-regulation of p21(WAF1/CIP1) by histone deacetylase inhibitors reduces their cytotoxicity. , 2001, Molecular pharmacology.

[50]  F. Dequiedt,et al.  Human HDAC7 Histone Deacetylase Activity Is Associated with HDAC3in Vivo * , 2001, The Journal of Biological Chemistry.

[51]  M. Guenther,et al.  The SMRT and N-CoR Corepressors Are Activating Cofactors for Histone Deacetylase 3 , 2001, Molecular and Cellular Biology.

[52]  Richard A. Rifkind,et al.  Cloning and characterization of a histone deacetylase, HDAC9 , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[53]  E. Bresnick,et al.  Histone acetylation beyond promoters: long‐range acetylation patterns in the chromatin world * , 2001, BioEssays : news and reviews in molecular, cellular and developmental biology.

[54]  T. Heinzel,et al.  Histone deacetylase as a therapeutic target , 2001, Trends in Endocrinology & Metabolism.

[55]  Ya-Li Yao,et al.  Regulation of Transcription Factor YY1 by Acetylation and Deacetylation , 2001, Molecular and Cellular Biology.

[56]  E. Miska,et al.  Differential localization of HDAC4 orchestrates muscle differentiation. , 2001, Nucleic acids research.

[57]  J. Black,et al.  Sp1 and krüppel‐like factor family of transcription factors in cell growth regulation and cancer , 2001, Journal of cellular physiology.

[58]  L. Grochow,et al.  A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[59]  M. Grever,et al.  Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[60]  E. Nicolas,et al.  The histone deacetylase HDAC3 targets RbAp48 to the retinoblastoma protein. , 2001, Nucleic acids research.

[61]  Jianqi Yang,et al.  Sodium Butyrate Induces Transcription from the Gαi2Gene Promoter through Multiple Sp1 Sites in the Promoter and by Activating the MEK-ERK Signal Transduction Pathway* , 2001, The Journal of Biological Chemistry.

[62]  Tae-Hee Han,et al.  14-3-3 associates with and activates the MEF2D transcription factor during muscle cell differentiation , 2001, Nucleic Acids Res..

[63]  M. Nishiyama,et al.  Histone deacetylase as a new target for cancer chemotherapy , 2001, Cancer Chemotherapy and Pharmacology.

[64]  Hui Li,et al.  SMRTe Inhibits MEF2C Transcriptional Activation by Targeting HDAC4 and 5 to Nuclear Domains* , 2001, The Journal of Biological Chemistry.

[65]  V. Della Pietra,et al.  Genes modulated by histone acetylation as new effectors of butyrate activity , 2001, FEBS letters.

[66]  Pier Giuseppe Pelicci,et al.  Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias? , 2001, Oncogene.

[67]  M. Downes,et al.  A Dynamic Role for HDAC7 in MEF2-mediated Muscle Differentiation* , 2001, The Journal of Biological Chemistry.

[68]  R. Muschel,et al.  Paradoxical effects of trichostatin A: inhibition of NF-Y-associated histone acetyltransferase activity, phosphorylation of hGCN5 and downregulation of cyclin A and B1 mRNA. , 2001, Cancer letters.

[69]  P. Marks,et al.  The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid. , 2001, Cancer research.

[70]  A. Harel-Bellan,et al.  Histone acetylation and disease , 2001, Cellular and Molecular Life Sciences CMLS.

[71]  M. Posch,et al.  Homo-oligomerisation and nuclear localisation of mouse histone deacetylase 1. , 2001, Journal of molecular biology.

[72]  P. Wade Transcriptional control at regulatory checkpoints by histone deacetylases: molecular connections between cancer and chromatin. , 2001, Human molecular genetics.

[73]  R C Coombes,et al.  Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[74]  A. Verdel,et al.  Functional significance of histone deacetylase diversity. , 2001, Current opinion in genetics & development.

[75]  C. Cordon-Cardo,et al.  Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[76]  S. Cooper,et al.  Revisiting retinoblastoma protein phosphorylation during the mammalian cell cycle , 2001, Cellular and Molecular Life Sciences CMLS.

[77]  F. Baas,et al.  The Human Transcriptome Map: Clustering of Highly Expressed Genes in Chromosomal Domains , 2001, Science.

[78]  P. Pelicci,et al.  Inhibition of histone deacetylase activity by trichostatin A modulates gene expression during mouse embryogenesis without apparent toxicity. , 2001, Cancer research.

[79]  M. Carducci,et al.  Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis. , 2001, Cancer research.

[80]  G. Otterson,et al.  DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. , 2001, Cancer research.

[81]  T. Ekström,et al.  The human histone deacetylase family. , 2001, Experimental cell research.

[82]  M. Yoshida,et al.  Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[83]  Jianqi Yang,et al.  promoter through multiple Sp1 sites in the promoter and by activating the MEK-ERK signal transduction pathway , 2001 .

[84]  小澤 幸泰 Histone deacetylase 3 associates with and represses the transcription factor GATA-2 , 2001 .

[85]  H. W. Lee,et al.  Activation of p21(WAF1/Cip1) transcription through Sp1 sites by histone deacetylase inhibitor apicidin: involvement of protein kinase C. , 2001, The Journal of biological chemistry.

[86]  J. Herman,et al.  Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. , 2001, Cancer research.

[87]  N. Bertos,et al.  Class II histone deacetylases: structure, function, and regulation. , 2001, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[88]  S. Park,et al.  14-3-3tau associates with and activates the MEF2D transcription factor during muscle cell differentiation. , 2001, Nucleic acids research.

[89]  G. Bae,et al.  Activation of p 21 WAF 1 / Cip 1 Transcription through Sp 1 Sites by Histone Deacetylase Inhibitor Apicidin INVOLVEMENT OF PROTEIN KINASE , 2001 .

[90]  P G Pelicci,et al.  Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. , 2001, Cancer research.

[91]  P. Marks,et al.  Histone deacetylase inhibitors and retinoic acids inhibit growth of human neuroblastoma in vitro. , 2000, Medical and pediatric oncology.

[92]  E. Olson,et al.  Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation , 2000, Nature.

[93]  H. W. Lee,et al.  Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin. , 2000, Cancer research.

[94]  I. Adcock,et al.  Glucocorticoid Receptor Recruitment of Histone Deacetylase 2 Inhibits Interleukin-1β-Induced Histone H4 Acetylation on Lysines 8 and 12 , 2000, Molecular and Cellular Biology.

[95]  R. Evans,et al.  Identification of a nuclear domain with deacetylase activity. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[96]  A. Moon,et al.  Apicidin, an inhibitor of histone deacetylase, prevents H-ras-induced invasive phenotype. , 2000, Cancer letters.

[97]  P. Marks,et al.  Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[98]  J. Clark,et al.  Cloning and characterization of a novel human histone deacetylase, HDAC8. , 2000, The Biochemical journal.

[99]  K. Imai,et al.  Histone deacetylase inhibitors suppress IL-2-mediated gene expression prior to induction of apoptosis. , 2000 .

[100]  J. Mariadason,et al.  Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids: comparison with trichostatin A, sulindac, and curcumin and implications for chemoprevention of colon cancer. , 2000, Cancer research.

[101]  P. Marks,et al.  Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. , 2000, Journal of the National Cancer Institute.

[102]  J. Neefs,et al.  Cloning and characterization of human histone deacetylase 8 , 2000, FEBS letters.

[103]  Wen‐Ming Yang,et al.  Histone Deacetylases Specifically Down-regulate p53-dependent Gene Activation* , 2000, The Journal of Biological Chemistry.

[104]  W. D. Cress,et al.  Histone deacetylases, transcriptional control, and cancer , 2000, Journal of cellular physiology.

[105]  S. Kern,et al.  A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of a compound library. , 2000, Cancer research.

[106]  James D. Winkler,et al.  Cloning and Characterization of a Novel Human Class I Histone Deacetylase That Functions as a Transcription Repressor* , 2000, The Journal of Biological Chemistry.

[107]  Hong Sun,et al.  Stra13 expression is associated with growth arrest and represses transcription through histone deacetylase (HDAC)-dependent and HDAC-independent mechanisms. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[108]  J. Herman,et al.  DNA hypermethylation in tumorigenesis: epigenetics joins genetics. , 2000, Trends in genetics : TIG.

[109]  J. Galmiche,et al.  Butyrate and trichostatin A effects on the proliferation/differentiation of human intestinal epithelial cells: induction of cyclin D3 and p21 expression , 2000, Gut.

[110]  T. Naoe,et al.  Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all‐trans retinoic acid , 2000, British journal of haematology.

[111]  P. Marks,et al.  Identification of a transcriptional repressor related to the noncatalytic domain of histone deacetylases 4 and 5. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[112]  C. Allis,et al.  The language of covalent histone modifications , 2000, Nature.

[113]  R. Evans,et al.  Isolation of a novel histone deacetylase reveals that class I and class II deacetylases promote SMRT-mediated repression. , 2000, Genes & development.

[114]  R. Eisenman,et al.  The Myc/Max/Mad network and the transcriptional control of cell behavior. , 2000, Annual review of cell and developmental biology.

[115]  P. Marks,et al.  Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors , 1999, Nature.

[116]  P. Marks,et al.  Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma. , 1999, Cancer research.

[117]  A. Bird,et al.  Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. , 1999, Genes & development.

[118]  H. Huang,et al.  Carboxypeptidase A3 (CPA3): a novel gene highly induced by histone deacetylase inhibitors during differentiation of prostate epithelial cancer cells. , 1999, Cancer research.

[119]  K. Georgopoulos,et al.  Repression by Ikaros and Aiolos is mediated through histone deacetylase complexes , 1999, The EMBO journal.

[120]  S. Horinouchi,et al.  Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase , 1999, Oncogene.

[121]  T. Tsuruo,et al.  A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[122]  J. Herman,et al.  Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer , 1999, Nature Genetics.

[123]  P. Pandolfi,et al.  Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. , 1998, Journal of the National Cancer Institute.

[124]  S. Gullans,et al.  Differential expression of human histone deacetylase mRNAs in response to immune cell apoptosis induction by trichostatin A and butyrate. , 1998, Biochemical and biophysical research communications.

[125]  Chi-Wai Wong,et al.  Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein , 1998, Oncogene.

[126]  J. Simons,et al.  Cytotoxic effects of sodium phenylbutyrate on human neuroblastoma cell lines. , 1998, International journal of oncology.

[127]  S. Schreiber,et al.  Depudecin induces morphological reversion of transformed fibroblasts via the inhibition of histone deacetylase. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[128]  Tony Kouzarides,et al.  Retinoblastoma protein recruits histone deacetylase to repress transcription , 1998, Nature.

[129]  C. Glass,et al.  A complex containing N-CoR, mSln3 and histone deacetylase mediates transcriptional repression , 1997, nature.

[130]  M. Berger,et al.  Efficacy of dinaline and its methyl and acetyl derivatives against colorectal cancer in vivo and in vitro. , 1996, European journal of cancer.

[131]  C. Van Lint,et al.  The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. , 1996, Gene expression.

[132]  M. Yoshida,et al.  Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. , 1993, The Journal of biological chemistry.

[133]  Histone deacetylase , 1993, FEBS letters.

[134]  M. Yoshida,et al.  Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. , 1990, Journal of Biological Chemistry.

[135]  J. Bender,et al.  Phase I Trial , 1983 .

[136]  H. Stähelin,et al.  Cytostatic activity of chlamydocin, a rapidly inactivated cyclic tetrapeptide. , 1974, European journal of cancer.

[137]  D. Lorimer,et al.  Cloning and characterization of a novel human histone deacetylase , HDAC 8 , 2022 .